Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

Sean M Post, PhD, Huaxian Ma, MS, Vivian Ruvolo, Xiaorui Zhang, BS, Tomoko Yasuhiro, Kohei Tanaka, Ryohei Kozaki, Toshio Yoshizawa, PhD, Jorge E. Cortes, MD, Courtney D. DiNardo, MDMSc, Marina Y Konopleva, MD PhD, Steven M. Kornblau, MD, Joseph D. Khoury, MD, Michael Andreeff, MD PhD, Peter P. Ruvolo, PhD

Blood (2019) 134 (Supplement_1): 2550.

https://doi.org/10.1182/blood-2019-128626

Published: 2019

Journal Articles

hnRNP K Overexpression Drives Myeloid Malignancy Via Interaction with RUNX1

Marisa J Hornbaker, BS, Prerna Malaney, PhD, Xiaorui Zhang, BS, Ruizhi Duan, M.Sc., Vrutant Shah, PhD, Shelley Herbrich, MS, Miguel Gallardo, PhD, Rodrigo Jacamo, PhD, Todd Link, PhD, Huaxian Ma, MS, Sanzhar Alybayev, MS, Steven M. Kornblau, MD, Peter Hu, PhD, Dos Sarbassov, PhD, Rashmi Kanagal-Shamanna, MD, Carlos E. Bueso-Ramos, MD PhD, Sean M Post, PhD

Blood (2018) 132 (Supplement 1): 2622.

https://doi.org/10.1182/blood-2018-99-117387

Published: 2018

Journal Articles

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

Peter P. Ruvolo, PhD, Huaxian Ma, MS, Vivian Ruvolo, MS, Xiaorui Zhang, BS, Hong Mu, MD PhD, Tomoko Yasuhiro, Kohei Tanaka, Toshio Yoshizawa, PhD, Weiguo Zhang, MD PhD, Jorge E. Cortes, MD, Michael Andreeff, MD PhD, Sean M Post, PhD

Blood (2018) 132 (Supplement 1): 2642.

https://doi.org/10.1182/blood-2018-99-112211

Published: 2018

Journal Articles

Combination Therapy with BTK Inhibitor Plus Anti-PD-1 Antibody Results in a Hyperprogressor Phenotype in a Mouse Model of CLL

Aidi Gu, PhD, Huaxian Ma, MS, Xiaorui Zhang, BS, Prerna Malaney, PhD, Miguel Gallardo, PhD, Jingwei Liu, MD, Sattva S. Neelapu, MD, Sean M Post, PhD

Blood (2018) 132 (Supplement 1): 4416.

https://doi.org/10.1182/blood-2018-99-118773

Published: 2018

Journal Articles

hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis

Blood (2018) 132 (Supplement 1): 1346.

https://doi.org/10.1182/blood-2018-99-116163

Published: 2018

Journal Articles

hnRNP K: A Driver of Myeloid Malignancy

Marisa J Hornbaker, BS, Miguel Gallardo, PhD, Xiaorui Zhang, BS, Prerna Malaney, PhD, Shelley Herbrich, MS, Huaxian Ma, Peter Hu, PhD, Steven Kornblau, MD, Carlos E. Bueso-Ramos, MD PhD, Sean M Post, PhD

Blood (2017) 130 (Supplement 1): 2511.

https://doi.org/10.1182/blood.V130.Suppl_1.2511.2511

Published: 2017

Journal Articles

hnRNP K Overexpression Drives AML Progression By Altering Pathways Critical for Myeloid Proliferation and Differentiation

Marisa J Hornbaker, BS, Miguel Gallardo, PhD, Xiaorui Zhang, BS, Huaxian Ma, BS, Peter Hu, PhD, Joseph D Khoury, MD, Steven M. Kornblau, MD, Carlos E Bueso-Ramos, MD PhD, Sean M. Post, PhD

Blood (2016) 128 (22): 744.

https://doi.org/10.1182/blood.V128.22.744.744

Published: 2016

Journal Articles

AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells

Peter Ruvolo, PhD, Huaxian Ma, BS, Vivian Ruvolo, MS, Hong Mu, MD PhD, Wendy Schober, Tomoko Yasuhiro, Toshio Yoshizawa, PhD, Miguel Gallardo, PhD, Xiaorui Zhang, BS, Joseph D Khoury, MD, Jorge Cortes, MD, Michael Andreeff, MD PhD, Sean M. Post, PhD

Blood (2016) 128 (22): 3939.

https://doi.org/10.1182/blood.V128.22.3939.3939

Published: 2016

Journal Articles

hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML

Miguel Gallardo, PhD, Hun Ju Lee, MD, Xiaorui Zhang, BS, Carlos E. Bueso-Ramos, MD, Laura Pageon, Mark McArthur, Asha Multani, Aziz Nazha, MD, Taghi Manshouri, PhD, Jan Parker-Thornburg, Peter Hu, Yuan Qi, Xiaoping Su, PhD, Inmaculada Rapado, Alfonso Quintás-Cardama, Steven M. Kornblau, MD, Joaquin Martinez-López, MDPhD, Sean M. Post, PhD

Blood (2015) 126 (23): 439.

https://doi.org/10.1182/blood.V126.23.439.439

Published: 2015

Journal Articles

Developing Therapeutic Strategies for CLL with Mutant p53

Hun Ju Lee, MD, Miguel Gallardo, PhD, Xiaorui Zhang, BS, Huaxian Ma, BS, Alfonso Quintas-Cardama, MD, Yuan Qi, Xiaoping Su, PhD, Sean M. Post, PhD

Blood (2015) 126 (23): 2476.

https://doi.org/10.1182/blood.V126.23.2476.2476

Published: 2015

Journal Articles

Amplification of hnRNP K Drives c-Myc-Dependent Malignancies and Represent a Novel Therapeutic Opportunity for Hematologic Malignancies

Miguel Gallardo, PhD, Xiaorui Zhang, BS, Mark McArthur, Taghi Manshouri, PhD, Sean M. Post, PhD

Blood (2015) 126 (23): 468.

https://doi.org/10.1182/blood.V126.23.468.468

Published: 2015

Journal Articles

hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression

Miguel Gallardo, PhD, Hun Ju Lee, MD, Xiaorui Zhang, Laura R. Pageon, Asha Multani, Markus Reschke, PhD, John G Clohessy, Alfonso Quintás-Cardama, MD, Michael Andreeff, MD PhD, Steven M. Kornblau, MD, Pier Paolo Pandolfi, MD PhD, Sean M. Post, PhD

Blood (2014) 124 (21): 2382.

https://doi.org/10.1182/blood.V124.21.2382.2382

Published: 2014

Journal Articles

hnRNP K : A Tumor Suppressor or Oncogene?

Miguel Gallardo, PhD, Hun Ju Lee, MD, Carlos E. Bueso-Ramos, MD PhD, Xiaorui Zhang, Laura R. Pageon, Asha Multani, Inmaculada Rapado, Alfonso Quintás-Cardama, MD, Steven M. Kornblau, MD, Joaquin Martinez-Lopez, Sean M. Post, PhD

Blood (2014) 124 (21): 259.

https://doi.org/10.1182/blood.V124.21.259.259

Published: 2014

Journal Articles

p53 Pathway Alterations Influence Survival and Treatment Response In Chronic Lymphocytic Leukemia

Hun Ju Lee, MD, Miguel Gallardo, PhD, Xiaorui Zhang, Alfonso Quintas-Cardama, Sean M. Post, PhD

Blood (2013) 122 (21): 2885.

https://doi.org/10.1182/blood.V122.21.2885.2885

Published: 2013

Journal Articles

Altered Expression and Mutation Analysis Of Heterogeneous Nuclear Ribonucleoprotein k In Bone Marrow Of Primary Myelofibrosis Patients

Ksenija Bozinovic, Taghi Manshouri, Ph.D., Sean M. Post, PhD, Ying Zhang, Miguel Gallardo, Ph.D, Xiaorui Zhang, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 5272.

https://doi.org/10.1182/blood.V122.21.5272.5272

Published: 2013

Journal Articles

hnRNP K: A Novel Regulator of Hematopoiesis and A Potential Predictive Biomarker In Acute Myeloid Leukemia

Miguel Gallardo, PhD, Hun Ju Lee, MD, Xiaorui Zhang, Aziz Nazha, MD, Laura R. Pageon, Steven M. Kornblau, MD, Alfonso Quintás-Cardama, MD, Sean M. Post, PhD

Blood (2013) 122 (21): 226.

https://doi.org/10.1182/blood.V122.21.226.226

Published: 2013

Journal Articles

High p53 Protein Expression LEVEL Independent Of Mutational Status Is An Adverse Prognostic Factor For Survival In ACUTE Myeloid Leukemia

Alfonso Quintas-Cardama, MD, Sean M. Post, PhD, Kensuke Kojima, MD, PhD, Yi Hua Qiu, MD, Michael Andreeff, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, Steven M. Kornblau, MD

Blood (2013) 122 (21): 1330.

https://doi.org/10.1182/blood.V122.21.1330.1330

Published: 2013

Journal Articles

BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status

Connie A Larsson, Kensuke Kojima, MD, PhD, Yong Wang, PhD, Nicholas Navin, PhD, Miguel Gallardo, PhD, Daniel Primo, Jose L. Rojas, Joaquin Martinez, Taghi Manshouri, Ph.D., Hun Ju Lee, MD, James E Bradner, MD, Juan Ballesteros, Sean M. Post, PhD, Guillermina (Gigi) Lozano, PhD, Alfonso Quintás-Cardama, MD

Blood (2013) 122 (21): 876.

https://doi.org/10.1182/blood.V122.21.876.876

Published: 2013

NARROW

AXL/Mertk Inhibitor ONO-7475 Potently Synergizes with BCL2 Inhibitor ABT-199, Overcomes ABT-199 Resistance Mechanisms, and Kills FLT3 ITD AML Cells

hnRNP K Overexpression Drives Myeloid Malignancy Via Interaction with RUNX1

TAM Inhibitor ONO-7475 Combination with Sorafenib Is Effective Using in Vitro and In Vivo Models of FLT3 ITD Acute Myeloid Leukemia

Combination Therapy with BTK Inhibitor Plus Anti-PD-1 Antibody Results in a Hyperprogressor Phenotype in a Mouse Model of CLL

hnRNP K: A Regulator of Global Transcription and Translation That Drives Lymphomagenesis

hnRNP K: A Driver of Myeloid Malignancy

hnRNP K Overexpression Drives AML Progression By Altering Pathways Critical for Myeloid Proliferation and Differentiation

AXL Inhibitor ONO-9330547 Suppresses PLK1 Gene and Protein Expression and Effectively Induces Growth Arrest and Apoptosis in FLT3 ITD Acute Myeloid Leukemia Cells

hnRNP K Is a Novel Haploinsufficient Tumor Suppressor at the 9q21.32 Locus That Defines a Subset of AML

Developing Therapeutic Strategies for CLL with Mutant p53

Amplification of hnRNP K Drives c-Myc-Dependent Malignancies and Represent a Novel Therapeutic Opportunity for Hematologic Malignancies

hnRNP K Overexpression Synergizes with Mutant NPM1 to Drive Acute Myeloid Leukemia Progression

hnRNP K : A Tumor Suppressor or Oncogene?

p53 Pathway Alterations Influence Survival and Treatment Response In Chronic Lymphocytic Leukemia

Altered Expression and Mutation Analysis Of Heterogeneous Nuclear Ribonucleoprotein k In Bone Marrow Of Primary Myelofibrosis Patients

hnRNP K: A Novel Regulator of Hematopoiesis and A Potential Predictive Biomarker In Acute Myeloid Leukemia

High p53 Protein Expression LEVEL Independent Of Mutational Status Is An Adverse Prognostic Factor For Survival In ACUTE Myeloid Leukemia

BET Bromodomain Inhibition Reduces Leukemic Burden and Prolongs Survival In The Eμ-TCL1 Transgenic Mouse Model Of Chronic Lymphocytic Leukemia (CLL) Independent Of TP53 Mutation Status

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only